Myeloma Advocacy Group Criticizes House Passage of American Health Care Act
The International Myeloma Foundation (IMF) says it is deeply worried that the American Health Care Act (AHCA) — which narrowly passed the U.S. House of…
Inês Martins, PhD, managing science editor — 
Articles by Inês Martins
Documentary Chronicles Record Run for a Departed Friend and Myeloma Research
A new documentary, “200 Miles,” tells the inspiring story of ultra-marathoner Eric Gelber’s determination to complete 33 loops of New York’s Central Park to…
Phase 1 Actimab-M Trial at Baylor Recruiting Heavily Treated Myeloma Patients
Multiple myeloma patients who received at least three prior lines of therapy and whose cancer expresses the CD33 molecule may enroll in the recently opened…
Multiple Myeloma Marathon Runner Don Wright, 76, Races Again in Philadelphia
Don Wright, the 76-year-old marathon runner who recently reached his goal of running 100 marathons after being diagnosed with multiple myeloma, ran Philadelphia’s Miles for…
Microfluidic Device May Replace Bone Marrow Biopsies for Myeloma
Patients with multiple myeloma soon may be diagnosed and followed solely with the use of a blood sample, avoiding the painful process of collecting a…
FDA Grants Tasquinimod Orphan Drug Status to Treat Multiple Myeloma
The small molecule immunomodulatory drug tasquinimod has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of multiple…
Hematologist-Oncologist to Lead Innovative NYU Bone Marrow Transplant Initiative
Syrian-born hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead an innovative program at NYU Langone’s Perlmutter Cancer Center for treating blood cancers, including multiple…
Amgen Applies to FDA Requesting Approval of Xgeva to Treat Multiple Myeloma
Amgen submitted a supplemental Biologics Licence Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of Xgeva…
Genetically Modified KITE-585 Therapy Increases Survival in Mice with Myeloma, Study Shows
Kite Pharma’s genetically modified T-cell therapy KITE-585 has delayed tumor progression and increased survival in mice with multiple myeloma, according to a preclinical-trial study. The…
Poseida’s P-BCMA-101 Eliminates Tumors in Mice with Multiple Myeloma, Studies Show
Poseida Therapeutics‘ P-BCMA-101 eradicates tumors in mouse models of multiple myeloma and creates memory T-cells that go on the attack when the disease returns, preclinical…